The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.